Chronic hepatitis B and D (delta) : Current and future treatments

Der Internist
N WortmannM Cornberg

Abstract

Worldwide, hepatitis B virus (HBV) infection is among the 30 leading causes of death, despite effective vaccination and therapeutic options. Chronic hepatitis delta (coinfection with hepatitis D virus) leads to a rapid disease progression. Based on current international guidelines and studies, an overview about present and future therapeutic options for chronic hepatitis B and delta is provided. Therapy with nucleoside or nucleotide analogues leads to nearly complete HBV DNA suppression, which is associated with regression of liver fibrosis and a lower risk for the development of hepatocellular carcinoma. Therapy of chronic hepatitis delta with pegylated interferon alfa achieves only low response rates with high risk for virological relapse. Various therapeutic approaches are currently being investigated in preclinical and clinical studies and have led to a significant reduction of hepatitis B surface antigen (HBsAg) and HDV RNA. Current therapies of chronic HBV infection can effectively reduce subsequent complications. New therapeutic approaches promise functional cure (HBsAg loss) of HBV infection and effective treatment options for patients with chronic hepatitis delta.

References

Jan 7, 2010·Nature Reviews. Gastroenterology & Hepatology·Heiner Wedemeyer, Michael P Manns
Jul 13, 2011·Zeitschrift für Gastroenterologie·M CornbergUNKNOWN AWMF
Mar 4, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Benjamin HeidrichUNKNOWN HIDIT-1 Study Group
Mar 29, 2014·Journal of Viral Hepatitis·B Calle SerranoH Wedemeyer
Apr 29, 2014·Gastroenterology·Stephan UrbanFabien Zoulim
Dec 23, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Carlo Ferrari
Apr 15, 2015·Antimicrobial Agents and Chemotherapy·Eisuke MurakamiAdrian S Ray
Nov 14, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Norah A TerraultUNKNOWN American Association for the Study of Liver Diseases
Apr 23, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·George PapatheodoridisJörg Petersen
Oct 22, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Seung-Ah LeeWilliam S Blaner
Oct 30, 2016·The Journal of Infectious Diseases·Christoph Höner Zu SiederdissenMarkus Cornberg
Oct 30, 2016·Current Opinion in Virology·Anika Wranke, Heiner Wedemeyer
Jan 5, 2017·Liver International : Official Journal of the International Association for the Study of the Liver·Barbara TestoniFabien Zoulim
Apr 22, 2017·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Oct 29, 2017·Journal of Hepatology·Henrik MuellerHassan Javanbakht
Nov 21, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Cihan YurdaydinJeffrey S Glenn
Feb 1, 2018·Nature Reviews. Gastroenterology & Hepatology·Markus Cornberg, Michael P Manns
Feb 11, 2018·Liver International : Official Journal of the International Association for the Study of the Liver·Florian van Bömmel, Thomas Berg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Related Papers

Visceral Medicine
Christoph Höner Zu Siederdissen, M Cornberg
Nederlands tijdschrift voor geneeskunde
R ZoutendijkRobert A de Man
Clinics and Research in Hepatology and Gastroenterology
Stéphane Chevaliez
Hepatitis Monthly
Maryam KeshvariMohammad Gholami Fesharaki
© 2022 Meta ULC. All rights reserved